Melanie M. Frigault

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia”.

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1130

N/A

3.1DataRank · unranked

79 citations

James S. Blachly, Kerry A. Rogers, Seema A. Bhat, Mojgan Jianfar, Gerard Lozanski +11 more

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

Leukemia(2022)10.1038/s41375-022-01758-z

N/A

0DataRank · unranked

37 citations

Ethan C. Whipp, Janek S. Walker, Pu Zhang, Larry Beaver, Katie Williams +21 more

Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma

British Journal of Haematology(2025)10.1111/bjh.70234

N/A

0DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, Svetlana Pack, Anna Marie Juanitez, Ahmed Hamdy +8 more